Alzheimer's disease drug development and the problem of the blood-brain barrier

Alzheimer's disease drug development and the problem of the blood-brain barrier

Abstract Alzheimer's disease (AD) drug development is limited by the presence of the blood-brain barrier (BBB). More than 98% of all small-molecule drugs, and ∼100% of all large-molecule drugs, do not cross the BBB. Although the vast majority of AD drug candidates do not cross the BBB, the pres...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alzheimer's & dementia 2009-09, Vol.5 (5), p.427-432
1. Verfasser: Pardridge, William M
Format: Artikel
Sprache:eng
Schlagworte:
Alzheimer Disease - drug therapy
Alzheimer Disease - metabolism
Biopharmaceuticals
Blood-brain barrier
Blood-Brain Barrier - drug effects
Blood-Brain Barrier - physiology
Brain drug targeting
Central Nervous System Agents - pharmacokinetics
Drug Delivery Systems - methods
Drug Design
Endogenous transporters
Humans
Neurology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 432
container_issue 5
container_start_page 427
container_title Alzheimer's & dementia
container_volume 5
creator Pardridge, William M
description Abstract Alzheimer's disease (AD) drug development is limited by the presence of the blood-brain barrier (BBB). More than 98% of all small-molecule drugs, and ∼100% of all large-molecule drugs, do not cross the BBB. Although the vast majority of AD drug candidates do not cross the BBB, the present-day AD drug-development effort is characterized by an imbalance wherein >99% of the drug-development effort is devoted to central nervous system (CNS) drug discovery, and
doi_str_mv 10.1016/j.jalz.2009.06.003
format Article
fullrecord <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2756824</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1552526009020901</els_id><sourcerecordid>ALZJJALZ200906003</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6323-aee126c0d360720cdcb6987abc28864822789f33537104ce574de8c1feab68c43</originalsourceid><addsrcrecordid>eNqNkk1v1DAQhi0Eoh_wBzig3DgljJ3EcSRUaVUBpVqpB-DCxXLsSdfBiVf27lbbX49DqvJxQBz8Pe87o8dDyCsKBQXK3w7FoNx9wQDaAngBUD4hp7SuWV6zpn36uOdwQs5iHAAqELR-Tk5o29S0ZeyU3Kzc_QbtiOFNzIyNqCJmJuxvM4MHdH474rTL1GSy3QazbfCdwzHz_c9j57w3eReUnbJOhWAxvCDPeuUivnxYz8nXD--_XF7l65uPny5X61zzkpW5QqSMazAlh4aBNrrjrWhUp5kQvBKMNaLty7IuGwqVxrqpDApNe1QdF7oqz8nF4rvddyManaoMysltsKMKR-mVlX--THYjb_1Bsqbmgs0GbDHQwccYsH_UUpAzXjnIGa-c8UrgMuFNote_Z_0leeCZAlZLwJ11ePwPS7laf7u-TtN8B3xJ8m7xwMTvkJjKqC1OGo0NqHfSePvvGi_-kmtnJ6uV-45HjIPfhyn9jKQyMgny89wkc4-k9CwNWv4AUqa1vQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Alzheimer's disease drug development and the problem of the blood-brain barrier</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Pardridge, William M</creator><creatorcontrib>Pardridge, William M</creatorcontrib><description>Abstract Alzheimer's disease (AD) drug development is limited by the presence of the blood-brain barrier (BBB). More than 98% of all small-molecule drugs, and ∼100% of all large-molecule drugs, do not cross the BBB. Although the vast majority of AD drug candidates do not cross the BBB, the present-day AD drug-development effort is characterized by an imbalance wherein &gt;99% of the drug-development effort is devoted to central nervous system (CNS) drug discovery, and &lt;1% of drug development is devoted to CNS drug delivery. Future AD drug development needs a concerted effort to incorporate BBB sciences early in the CNS drug discovery process. This goal can be achieved by a reallocation of resources, and an expansion of research efforts in the pure science of BBB biology and the applied science of brain drug-targeting technology.</description><identifier>ISSN: 1552-5260</identifier><identifier>EISSN: 1552-5279</identifier><identifier>DOI: 10.1016/j.jalz.2009.06.003</identifier><identifier>PMID: 19751922</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Alzheimer Disease - drug therapy ; Alzheimer Disease - metabolism ; Biopharmaceuticals ; Blood-brain barrier ; Blood-Brain Barrier - drug effects ; Blood-Brain Barrier - physiology ; Brain drug targeting ; Central Nervous System Agents - pharmacokinetics ; Drug Delivery Systems - methods ; Drug Design ; Endogenous transporters ; Humans ; Neurology</subject><ispartof>Alzheimer's &amp; dementia, 2009-09, Vol.5 (5), p.427-432</ispartof><rights>The Alzheimer's Association</rights><rights>2009 The Alzheimer's Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6323-aee126c0d360720cdcb6987abc28864822789f33537104ce574de8c1feab68c43</citedby><cites>FETCH-LOGICAL-c6323-aee126c0d360720cdcb6987abc28864822789f33537104ce574de8c1feab68c43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1016%2Fj.jalz.2009.06.003$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1016%2Fj.jalz.2009.06.003$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19751922$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pardridge, William M</creatorcontrib><title>Alzheimer's disease drug development and the problem of the blood-brain barrier</title><title>Alzheimer's &amp; dementia</title><addtitle>Alzheimers Dement</addtitle><description>Abstract Alzheimer's disease (AD) drug development is limited by the presence of the blood-brain barrier (BBB). More than 98% of all small-molecule drugs, and ∼100% of all large-molecule drugs, do not cross the BBB. Although the vast majority of AD drug candidates do not cross the BBB, the present-day AD drug-development effort is characterized by an imbalance wherein &gt;99% of the drug-development effort is devoted to central nervous system (CNS) drug discovery, and &lt;1% of drug development is devoted to CNS drug delivery. Future AD drug development needs a concerted effort to incorporate BBB sciences early in the CNS drug discovery process. This goal can be achieved by a reallocation of resources, and an expansion of research efforts in the pure science of BBB biology and the applied science of brain drug-targeting technology.</description><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - metabolism</subject><subject>Biopharmaceuticals</subject><subject>Blood-brain barrier</subject><subject>Blood-Brain Barrier - drug effects</subject><subject>Blood-Brain Barrier - physiology</subject><subject>Brain drug targeting</subject><subject>Central Nervous System Agents - pharmacokinetics</subject><subject>Drug Delivery Systems - methods</subject><subject>Drug Design</subject><subject>Endogenous transporters</subject><subject>Humans</subject><subject>Neurology</subject><issn>1552-5260</issn><issn>1552-5279</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkk1v1DAQhi0Eoh_wBzig3DgljJ3EcSRUaVUBpVqpB-DCxXLsSdfBiVf27lbbX49DqvJxQBz8Pe87o8dDyCsKBQXK3w7FoNx9wQDaAngBUD4hp7SuWV6zpn36uOdwQs5iHAAqELR-Tk5o29S0ZeyU3Kzc_QbtiOFNzIyNqCJmJuxvM4MHdH474rTL1GSy3QazbfCdwzHz_c9j57w3eReUnbJOhWAxvCDPeuUivnxYz8nXD--_XF7l65uPny5X61zzkpW5QqSMazAlh4aBNrrjrWhUp5kQvBKMNaLty7IuGwqVxrqpDApNe1QdF7oqz8nF4rvddyManaoMysltsKMKR-mVlX--THYjb_1Bsqbmgs0GbDHQwccYsH_UUpAzXjnIGa-c8UrgMuFNote_Z_0leeCZAlZLwJ11ePwPS7laf7u-TtN8B3xJ8m7xwMTvkJjKqC1OGo0NqHfSePvvGi_-kmtnJ6uV-45HjIPfhyn9jKQyMgny89wkc4-k9CwNWv4AUqa1vQ</recordid><startdate>200909</startdate><enddate>200909</enddate><creator>Pardridge, William M</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>200909</creationdate><title>Alzheimer's disease drug development and the problem of the blood-brain barrier</title><author>Pardridge, William M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6323-aee126c0d360720cdcb6987abc28864822789f33537104ce574de8c1feab68c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - metabolism</topic><topic>Biopharmaceuticals</topic><topic>Blood-brain barrier</topic><topic>Blood-Brain Barrier - drug effects</topic><topic>Blood-Brain Barrier - physiology</topic><topic>Brain drug targeting</topic><topic>Central Nervous System Agents - pharmacokinetics</topic><topic>Drug Delivery Systems - methods</topic><topic>Drug Design</topic><topic>Endogenous transporters</topic><topic>Humans</topic><topic>Neurology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pardridge, William M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Alzheimer's &amp; dementia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pardridge, William M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alzheimer's disease drug development and the problem of the blood-brain barrier</atitle><jtitle>Alzheimer's &amp; dementia</jtitle><addtitle>Alzheimers Dement</addtitle><date>2009-09</date><risdate>2009</risdate><volume>5</volume><issue>5</issue><spage>427</spage><epage>432</epage><pages>427-432</pages><issn>1552-5260</issn><eissn>1552-5279</eissn><abstract>Abstract Alzheimer's disease (AD) drug development is limited by the presence of the blood-brain barrier (BBB). More than 98% of all small-molecule drugs, and ∼100% of all large-molecule drugs, do not cross the BBB. Although the vast majority of AD drug candidates do not cross the BBB, the present-day AD drug-development effort is characterized by an imbalance wherein &gt;99% of the drug-development effort is devoted to central nervous system (CNS) drug discovery, and &lt;1% of drug development is devoted to CNS drug delivery. Future AD drug development needs a concerted effort to incorporate BBB sciences early in the CNS drug discovery process. This goal can be achieved by a reallocation of resources, and an expansion of research efforts in the pure science of BBB biology and the applied science of brain drug-targeting technology.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>19751922</pmid><doi>10.1016/j.jalz.2009.06.003</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1552-5260
ispartof Alzheimer's & dementia, 2009-09, Vol.5 (5), p.427-432
issn 1552-5260
1552-5279
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2756824
source Wiley Online Library - AutoHoldings Journals; MEDLINE
subjects Alzheimer Disease - drug therapy
Alzheimer Disease - metabolism
Biopharmaceuticals
Blood-brain barrier
Blood-Brain Barrier - drug effects
Blood-Brain Barrier - physiology
Brain drug targeting
Central Nervous System Agents - pharmacokinetics
Drug Delivery Systems - methods
Drug Design
Endogenous transporters
Humans
Neurology
title Alzheimer's disease drug development and the problem of the blood-brain barrier
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T14%3A43%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alzheimer's%20disease%20drug%20development%20and%20the%20problem%20of%20the%20blood-brain%20barrier&rft.jtitle=Alzheimer's%20&%20dementia&rft.au=Pardridge,%20William%20M&rft.date=2009-09&rft.volume=5&rft.issue=5&rft.spage=427&rft.epage=432&rft.pages=427-432&rft.issn=1552-5260&rft.eissn=1552-5279&rft_id=info:doi/10.1016/j.jalz.2009.06.003&rft_dat=%3Cwiley_pubme%3EALZJJALZ200906003%3C/wiley_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19751922&rft_els_id=1_s2_0_S1552526009020901&rfr_iscdi=true